Side-by-side · Research reference

BronchogenvsGHRP-2

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BPhase 2HUMAN-REVIEWED15/42 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Bronchogen

GHRP-2

Primary target

Bronchial epithelial cellsKuzubova 2015

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Feedback intact?

—

Yes, with somatostatin feedback active

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

GHRP-2

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Phase 2 + clinical diagnostic useBowers 1990

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose

—

100–300 mcg per injectionBowers 1990

Frequency

—

1–3× per day

Lower / starter dose

—

50 mcg per dose

Duration

—

8–12 weeks on / 4 off (anecdotal)

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~30 minMalagón 1999

04Side Effects & Safety

Parameter

Bronchogen

GHRP-2

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Cortisol elevation

—

Mild but measurableBowers 1990

Prolactin elevation

—

Mild but measurable

Hunger

—

Strong appetite increase

Injection site reaction

—

Mild erythema

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Bronchogen

—

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

Bronchogen

—

GHRP-2

·Untreated diabetes

05Administration Protocol

Parameter

Bronchogen

GHRP-2

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

SQ — abdomen or thigh. Rotate sites.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

Pre-sleep + fasted preferred.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Bronchogen

— no documented stacks

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006